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Background & objectives: New smear-positive pulmonary tuberculosis (PTB) patients in the Revised
National Tuberculosis Control Programme (RNTCP) are treated with a 6-month short-course
chemotherapy (SCC) regimen irrespective of co-morbid conditions. We undertook this retrospective
analysis to compare sputum conversion rates (smear, culture) at the end of intensive phase (IP) of
Category-1 regimen among patients admitted to concurrent controlled clinical trials: pulmonary
tuberculosis alone (PTB) or with type 2 diabetes mellitus (DM-TB) or HIV infection (HIV-TB), and
to identify the risk factors influencing sputum conversion.
Methods: In this retrospective analysis sputum conversion rates at the end of intensive phase (IP) in
three concurrent studies undertaken among PTB, DM-TB and HIV-TB patients, during 1998 –
2002 at the Tuberculosis Research Centre (TRC), Chennai, were compared. Sputum smears were
examined by fluorescent microscopy. HIV infected patients did not receive anti-retroviral treatment
(ART). Patients with DM were treated with oral hypoglycaemic drugs or insulin (sc).
Results: The study population included 98, 92 and 88 patients in the PTB, DM-TB and HIV-TB
studies. At the end of IP the smear conversion (58, 61, and 62%) and culture conversion (86, 88 and
92%) rates were similar in the three groups respectively. The variables associated with lack of
sputum smear or culture conversion were age >45 yr, higher pre-treatment smear and culture grading,
and extent of the radiographic involvement.
Interpretation & conclusions: Our findings confirm that the current policy of the control programme
to treat all pulmonary TB patients with or with out co-morbid conditions with Category-I regimen
appears to be appropriate.
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The Government of India’s Revised National
Tuberculosis Control Programme (RNTCP), based on
the DOTS strategy, began as a pilot in 1993 for effective
control of tuberculosis. By March 2006, it has expanded
to cover the entire population of India1. In the RNTCP,
new smear positive pulmonary TB patients are treated
with a 6 month short-course chemotherapy (Category-
1) regimen, which has an intensive phase of 2 months
duration with 4 drugs (isoniazid, rifampicin, ethambutol
and pyrazinamide) and a continuation phase of 4 months
with 2 drugs (isoniazid and rifampicin). The drugs are
given three times a week throughout the treatment
period. All new pulmonary TB patients are treated with
this regimen irrespective of associated co-morbid
conditions such as diabetes mellitus (DM) or HIV.
However, treatment of TB in diabetes may pose
problems as it has been reported that diabetic patients
have some degree of impaired gastrointestinal (GI) drug
absorption even in the absence of clinical gastroparesis2.
Moreover the hyperglycaemic state may additionally
interfere with achieving adequate tissue levels of the
medications, or with alveolar macrophage/CD4+ cell
function3.
For patients receiving Category-1 regimen in the
RNTCP, smear conversion at the end of the intensive
phase (IP) of treatment is emphasized as an important
early predictor of treatment success4-7.The sputum
conversion results are used both for management of
patients and for monitoring programme performance.
If the smear is positive, the intensive phase is extended
by one more month for that patient. It also indirectly
helps to verify whether DOT (Directly observed
treatment) is being carried out and thus serves as an
important evaluation indicator of programme
performance. Therefore it assumes importance in the
context of RNTCP as there are implications in terms of
treatment decisions that could be made mid-course.
 In this background, it is essential to evaluate risk
factors such as age, smear grading, weight and
associated co-morbid conditions like HIV infection and
diabetes mellitus among TB patients that are likely to
influence smear conversion. Although risk factors which
influence smear conversion have been studied widely8-10,
there are few studies on smear conversion in HIV co-
infected individuals11 but none with associated diabetes
mellitus.
We report here a retrospective analysis on
comparison of smear and culture conversion at the end
of the intensive phase of treatment in the three groups
of patients, namely pulmonary tuberculosis (PTB), PTB
with type 2 DM, and PTB with HIV infection and the
risk factors that influence sputum smear and culture
conversion in these patients. All these patients were
treated with RNTCP Category-1 regimen.
Material & Methods
Study design: This is a retrospective analysis of three
concurrent studies. The first study was a randomized
controlled clinical trial with an objective to evaluate
the efficacy of a 4 month regimen containing ofloxacin
in PTB patients, where Category-1 RNTCP regimen was
given to patients in the control arm. In the second study
the efficacy of Category-1 RNTCP regimen was
assessed in pulmonary TB patients with concomitant
type 2 diabetes mellitus (NIDDM) (DM-TB). The third
study was a randomized controlled clinical trial where
the efficacy of a 9-month regimen with an extended
continuation phase of 3 months was compared with the
Category-1 RNTCP regimen (control regimen) in PTB
patients with HIV co-infection (HIV-TB). These studies
were conducted at the Chennai and Madurai divisions
of Tuberculosis Research Centre (TRC), during 1998-
2002.
Eligibility criteria: In all these studies only new smear
positive pulmonary TB patients were enrolled. For the
DM-TB study, the eligibility criteria were as follows:
concomitant type 2 diabetes mellitus with plasma
creatinine level of < 2 mg/dl, absence of acetone in urine
and non-reactive for HIV. For the PTB study the patients
were eligible if aged > 18 yr, weight was >30 kg and
were HIV seronegative. For the HIV-TB study, HIV
seropositive patients aged > 15 yr were eligible for
enrollment. Patients in moribund state or with major
systemic illnesses or with abnormal biochemical profile
were not eligible for admission to any of these studies.
Pre-treatment assessment including investigations:
Prior to enrolment into the respective studies, informed
consent was obtained from all patients. All the studies
have been approved by our Institutional Ethics
Committee. A detailed history including previous anti-
tuberculosis therapy was elicited. Sociological
assessment including information on socio-
demographic profile was done. A general clinical
examination was performed and the patient’s weight
was recorded. Baseline investigations included chest
X-ray, and examination of four sputa by smear and
culture. X-rays were read by a panel of doctors to
evaluate (i) the extent of X-ray involvement which was
documented as unilateral or bilateral, (ii) the number
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of zones involved (minimum1zone - maximum 6 zones,
and (iii) presence or absence of cavitation12. HIV
screening was performed after pre-test counselling using
the Tridot Rapid (J. Mitra, India) test; all positive results
were confirmed using Comb Aids Rapid (Span
diagnostics, India) test and also by ELISA (J.Mitra,
India). Routine laboratory investigations including
estimation of Haemoglobin, total and differential
leucocyte cell count, blood sugar, blood urea, serum
creatinine, serum uric acid and liver functions were
performed.
In addition, for DM-TB patients estimation of
fasting blood sugar, lipid profile and glycosylated
HbA1c was done. In HIV-TB patients CD4, CD8 cell
counts and CD4/CD8 ratio were undertaken using
flowcytometer (Simultest-IMK Lymphocyte kit) and
tuberculin testing with 1TU of PPD RT 23.
Bacteriology: Sputum smears were examined for acid
fast bacilli (AFB) by fluorescence microscopy13 and the
specimens were processed by modified Petroff’s
method14 and cultured on the Lowenstein-Jensen (LJ)
medium. The sputum smears were graded according to
the number of bacilli visualized per high power field
(HPF) as follows: less than 6 bacilli per HPF (1+), 6-
100 bacilli per HPF (2+) and more than 100 bacilli per
HPF or large clumps (3+)13. The cultures were graded
based on the type of growth in the LJ medium as follows:
20-100 colonies growth (1+), >100 colonies (2+) and
confluent growth (3+)15. All positive cultures were
subjected to identification tests for Mycobacterium
tuberculosis and to drug susceptibility tests using the
minimal inhibitory concentration method for isoniazid
and rifampicin14,15. Drug resistance was defined as
minimal inhibitory concentration (MIC) of 1mg or more
for isoniazid and 128 mg for rifampicin16.
Treatment regimen and follow up: The patients who
fulfilled the eligibility criteria received Category-1
RNTCP regimen: 2 E3H3R3Z3 / 4 R3H3. The dosage used
for all these patients was as follows: ethambutol (E)
1200 mg, isoniazid (H) 600 mg, rifampicin (R) 450 mg
(600 mg > 60 kg) and pyrazinamide (Z) 1500 mg. As
recommended in the RNTCP extension of the intensive
phase for patients producing positive smears at 2 months
was not done for any of the patients. Treatment was
completely supervised for the entire 6 months. If the
patients failed to attend, home visits by the health visitor,
social worker and doctor were made to retrieve the
patients. For all patients, sputum smear and culture
examinations were undertaken at monthly intervals for
monitoring of progress. Patients were motivated for
regular treatment at every attendance.
A diabetologist from the Government General
Hospital (GH), Chennai monitored the diabetic status
of patients with a fasting blood sugar estimation every
month. Based on the blood sugar levels, they were either
treated with oral hypoglycaemic drugs, which was
collected from the department of diabetology at the GH
every month, or insulin for which arrangements were
made at our centre.
HIV infected patients received co-trimoxazole
regularly if their CD4 counts were < 250 cells/cu.mm.
However, none of the HIV infected patients received
anti-retroviral therapy (ART) as anti-retroviral treatment
was not available in the Government hospitals during
the period of this study.
Statistical analysis: SPSS version 13.0 Inc., Chicago,
II, USA was used for all statistical analysis. Trend Chi-
square test with Yates correction was used to compare
the proportions, Fisher’s exact test was used when the
expected value of a cell was less than 5. A backward
logistic regression was used to identify the independent
risk factors for bacteriological conversion at 2 months
after adjusting the effect of other factors. P<0.05 were
considered significant.
Results
Study population and baseline characteristics: A total of
278 smear-positive patients were enrolled into the study:
98 patients in the PTB group, 92 in the DM-TB group
and 88 in the HIV-TB group. In both HIV TB and PTB
studies there were no exclusions. While 100 patients were
enrolled in the DM-TB group, 6 were excluded as they
had missed more than 25 per cent of the scheduled
treatment and 2 patients had defaulted after initial 5 doses
of treatment. Males were 73, 78 and 82 per cent in the
PTB, DM-TB and HIV-TB group respectively. While the
median age of the patients in the cohort was 38 yr (range
17-70 yr), the median age of DM-TB patients was 48 yr
as compared to 31 yr in the PTB and 34 yr in the HIV-
TB group. The median weight was 44 kg, however it
was lowest in the HIV-TB group (42.6 kg) and was
highest in the PTB group (45 kg). The initial smear and
culture grading was highest (3+) in the PTB group and
lowest in HIV-TB group (Table I).
Only those patients who had received >75 per cent
of drug doses were considered for efficacy analysis.
Smear and culture conversion: At the end of intensive
phase, among 278 patients, smear negativity was
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observed in 168 (60%) patients. The end of intensive
phase culture conversion was observed in 246 (88%)
patients. The smear and culture conversion in the three
groups were as follows: PTB group (58, 86%), DM-
TB group (61, 88%) and HIV-TB group (62, 92%)
(Fig.). As there was no difference in the 3 groups with
reference to smear and culture conversion, the 3 groups
were amalgamated for further analysis.
Factors influencing smear conversion: The variables
associated with lack of sputum smear conversion at the
end of intensive phase among those analyzed were age
> 45 yr (P=0.01), being males (P=0.02), higher pre-
treatment smear grading (P<0.001), bilateral lung
involvement (P=0.02) and involvement of more than 2
radiographic zones (P<0.001) in chest X-ray (Table II).
On the other hand, presence of cavitation in the chest
Table I. Characteristics of the study population (n = 278)
PTB (n=98 ) DM-TB (n=92 ) HIV-TB (n=88 ) All (n=278 )
Sex Males 72(73) 72(78) 72(82) 216(78)
Age (yr) Median 31.0 48.0 34.0 38.0
Range 18-65 32-70 17-63 17-70
Weight (kg) Median 45.0 44.3 42.6 44.0
Range 29.0-74.7 31.5-74.0 18.5-70.0 18.5-74.7
Lung zones involved >2 zones 68(69) 58(63) 53(60) 179(64)
Extent of the disease Bilateral 64(65) 47(51) 59(67) 170(61)
Initial 1+ 28(29) 43(47) 50(57) 121(44)
   smear 2+ 49(50) 38(41) 34(39) 121(44)
   grading 3+ 21(21) 11(12) 4(4) 36(13)
Intitial < 1+ 4(4) 12(13) 26(29) 42(15)
   culture 2+ 19(19) 23(25) 28(32) 70(25)
   grading 3+ 75(77) 57(62) 34(39) 166(60)
Figures in parentheses are percentages
Table II. Factors related to smear and culture conversion at the end of intensive phase
Parameters Total Smear P value Culture P value
(278) negative negative
(168) (246)
n ( % ) n ( % )
Age (yr) < 45 192 126 (66) 0.01 179 (93) <0.001
> 45 86 42 (49) 67 (78)
Weight (kg) < 40 81 47 (58) NS 71 (88) NS
40-59.9 182 111 (61) 161 (88)
> 60 15 10 (67) 14 (93)
Sex Male 216 122 (56) 0.02 188 (87) NS
Female 62 46 (74) 58 (94)
Pre-treatment 1 + 121 93 (77)
smear grading 2 + 121 64 (53) < 0.001
3 + 36 11 (31)
Pre-treatment <1 + 42 41 (98) <0.001
culture grading 2 + 70 68 (97)
3 + 160 137 (83)
X-ray chest Extent Bilateral 170 93 (55) 0.02 145 (85) NS
of disease Unilateral 108 75 (69) 101 (93)
No. of zones involved > 2 179 94 (53) 152 (85) 0.02
< 2 99 74 (75) <0.001 94 (95)
Cavitation Yes 55 30 (55) 49 (89)
No 223 138 (62) NS 197 (88) NS
Pre-treatment Sensitive 260 158 (61) NS 233 (90) 0.04
susceptibility Resistant 18 10 (56) 13 (72)
H 16 9 (56) 11 (69)
R 2 1 (50) 2 (100)
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Table III. Logistic regression results for variables significantly associated with delayed sputum smear and culture conversion at the
end of Intensive phase
Dependent variable Independent variable Coefficient (B) SE Exp.(B) 95 % C I P value
Smear conversion Age 0.586 0.288 1.80 1.02 - 3.16 0.03
No. of zones involved 0.268 0.095 1.31 1.09 - 1.57 0.01
in chest X-ray
Pre-treatment smear grading 0.97 0.207 2.64 1.76 - 3.96 <0.001
Culture conversion Age 1.253 0.411 3.50 1.56 - 7.84 0.01
No. of zones involved in
chest X-ray 0.342 0.153 1.41 1.04 - 1.90 0.03
Pre-treatment culture grading 1.263 0.491 3.54 1.35 - 9.26 0.01
regimen was similar in PTB patients with or without
associated diabetes mellitus or HIV co-infection. These
were in conformity with the earlier studies8,10,11. The
likely reason could be that HIV patients have been found
to have a lower bacillary load in sputum compared to
HIV negative persons though the difference was not
statistically significant. We have also observed that there
was no difference in smear and culture conversion
between diabetics and non-diabetics. Hence the uniform
policy of treating all new smear-positive PTB patients
with Category-1 regimen irrespective of co-morbid
conditions is acceptable.
The low smear conversion rates observed in these
studies when compared with the national average is
likely to be due to the use of the fluorescent auramine
rhodamine stain which is known to be more sensitive
than the Ziehl-Neelsen stain in sputum smear reading
for acid fast bacilli17,18.
Factors such as age more than 45 yr, being males,
higher pre-treatment smear grading and bilateral
radiographic involvement with lesions in more than 2
zones were associated with lack of smear conversion.
Earlier studies have shown that higher the age, higher
is the lack of sputum smear conversion.8,9 The reason
might be that with advancing age there might be physical
disability resulting in increased delay in clearing the
bacilli probably due to decreasing immunity and also
delay in seeking care and diagnosis which might lead
to progression of the disease19,20. We have also observed
lack of smear conversion in males. This might be due
to associated habits like smoking and alcoholism
although these were not studied.
Patients with higher smear grading (2+ and 3+) prior
to treatment were less likely to convert compared to
patients with 1+ smear. Similar findings have been
reported earlier8-10. We have also observed that with
higher culture grading, a longer time is taken for culture
X-ray and pre-treatment drug resistance were not
associated with lack of sputum smear conversion.
Factors influencing culture conversion: The variables
associated with lack of culture conversion were age >45
yr (P<0.001), higher pre-treatment culture grading
(P<0.001), involvement of more than 2 radiographic
zones in the X-ray chest (P=0.02) and presence of pre-
treatment drug resistance (P=0.04) (Table II).
Logistic regression analysis showed that lack of
smear conversion at the end of intensive phase were
associated with age >45 yr (P=0.03), chest X-ray
involvement of more than 2 zones (P=0.01) and higher
pre-treatment smear grading (P<0.001), and lack of
culture conversion were associated with age >45 yr
(P=0.01), higher pre-treatment culture grading (P =0.01)
and radiographic involvement of more than 2 zones
(P=0.03) (Table III).
Discussion
The findings showed that smear and culture
conversion at the end of intensive phase of Category-1
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Fig. Smear and culture conversion at the end of 2 months of
intensive phase among PTB, DM-TB and HIV-TB.
conversion. Sputum smear and culture conversion
appeared to be good in patients with advanced
radiological disease, who were regular with Category-
1 regimen treatment.
Severity of the disease as assessed radiographically
showed that bilateral lesions and involvement of more
than 2 zones were associated with lack of sputum smear
and culture conversion. However, contrary to previous
studies, we observed that radiologically assessed
cavitation status was not related to sputum smear
conversion8-10.
In our series, the presence of pre-treatment isoniazid
or rifampicin resistance did not influence smear
conversion, as reported in earlier studies11,21. However,
lack of culture conversion was observed among patients
harbouring drug resistant bacilli. Although this
observation was based on 18 patients with resistant
organisms, it underscores the fact that if a patient
remains culture positive at 2 months, it would be wise
to undertake drug susceptibility tests eventhough drug
susceptibility testing is not possible at present under
the current programme conditions.
The limitation of this study was that this information
was based on selected patients enrolled into controlled
clinical trials who were chosen following rigid selection
criteria. It may not reflect the patterns in the community
in general. Moreover, they were treated with 2 months
of intensive phase with no extension even if sputum
was positive at the end of second month, which is not
in conformity with the RNTCP guidelines. Sputum
smear and culture conversion is likely to be
multifactorial in DM-TB and HIV-TB patients who may
have different risk factors for non-conversion at 2
months.
In conclusion, this study has shown that in sputum-
positive pulmonary TB patients treated with Category-
1 regimen, HIV co-infection or diabetes mellitus did
not affect smear and culture conversion. Therefore the
programme’s recommendation of treating all smear
positive pulmonary tuberculosis patients with Category-
1 regimen irrespective of associated co-morbid
conditions is appropriate as shown by examination of
this intermediate outcome of 2-month sputum smear
and culture conversion. However, these co-existing
conditions have to be given due consideration in order
to motivate patients regarding control of diabetes and
co-trimoxaole prophylaxis with recommended ART
regimens in HIV co-infected patients. The information
on risk factors identified in this study may be crucial
for policy makers to develop special guidelines for close
monitoring of these patients as prolonged infectiousness
may increase the transmission of disease in the
community, which might impede the impact of the TB
control programme. Programme managers should
develop special packages to monitor persons aged 45
yr or more and facilitate early diagnosis of the disease.
Acknowledgment
The authors thank the staff of Bacteriology, Pathology,
Biochemistry and Statistics Departments of TRC for their technical
assistance, and nursing staff and social workers for their help in
taking care of the patients. Authors acknowledge the Superintendent
and staff of the Government Hospital for Thoracic Medicine,
Tambaram, Prof.K.Jegannath, former Director of Institute of
Thoracic Medicine, Chennai  and Prof A.Sundaram, Head of the
Department of Diabetology, Kilpauk Medical College, Chennai  for
referring patients.
References
1. Available from: http://www.tbcindia.org/impRNTCP.asp,
accessed on May 2, 2006.
2. Bashar M, Alcabes P, Rom WN, Condos R. Increased incidence
of multidrug-resistant tuberculosis in diabetic patients on the
Bellevue Chest Service, 1987 to 1997. Chest 2001; 120 : 1514-
9.
3. Ljubic S, Balachandar A, Pavlic Renar I, Barada A, Metelko
Z. Pulmonary infections in diabetes mellites. Diabetol Croat
2004; 33 : 115-24
4. Rieder HL. Sputum smear conversion during directly observed
treatment for tuberculosis. Tuber Lung Dis 1996; 77 : 124-9.
5. Zhao FZ, Levy MH, Wen S. Sputum microscopy results at
two and three months predict outcome of tuberculosis
treatment. Int J Tuberc Lung Dis 1997; 1 : 570-2.
6. Wen S, Su Y, Zhang F. Analysis of short-term effects of short-
course intermittent chemotherapies of the World bank Loaned
Project. Zhonghua Jie He He Hu Xi Za Zhi 1996; 19 : 357-9.
7. Chavez Pachas AM, Blank R, Smith Fawzi MC, Bayona J,
Becerra MC, Mitnick CD. Identifying early treatment failure
on Category 1 therapy for pulmonary tuberculosis in Lima
Ciudad, Peru. Int J Tuberc Lung Dis 2004; 8 : 52-8.
8. Dominguez-Castellano A, Muniain MA, Rodriguez-Bano J,
Garcia M, Rios, MJ, Galvez J, et al. Factors associated with
time to sputum smear conversion in active pulmonary
tuberculosis. Int J Tuberc Lung Dis 2003; 7 : 432-8.
9. Singla R, Osman MM, Khan N, Al-Sharif N, Al-Sayegh MO,
Shaikh MA. Factors predicting persistent sputum smear
positivity among pulmonary tuberculosis patients 2 months
after treatment. Int J Tuberc Lung Dis 2003; 7 : 58-64.
10. Telzak EE, Fazal BA, Pollard CL, Turett GS, Justman JE, Blum
S. Factors influencing time to sputum conversion among
patients with smear-positive pulmonary tuberculosis. Clin
Infect Dis 1997; 25 : 666-70.
11. Bwire R, Borgdorff MW, Sticht-Groh V, Rieder HL, Kawuma
HJ, Bretzel G, et al. Tuberculosis chemotherapy and sputum
conversion among HIV-seropositive and HIV-seronegative
patients in south-eastern Uganda. East Afr Med J 1999; 76 :
307-13.
BANU REKHA et al: SPUTUM CONVERSION IN TB WITH DIABETES MELLITUS OR HIV 457
12. Arthur JA Wrightman. Diagnostic Imaging. In: Seaton A,
Seaton D, Leitch AG, editors. Crofton and Douglas’s
respiratory diseases, 5th ed., Oxford: Blackwell Science Pvt.
Ltd; 2000 p.119-47.
13. Holst E, Mitchison DA, Radhakrishna S. Examination of
smears for tubercle bacilli by fluorescence microscopy. Indian
J Med Res 1959; 47 : 495-9.
14. Kent PT, Kubica GP. Isolation procedures. In: Public health
mycobacteriology. A guide for Level 3 laboratory. Atlanta,
Georgiar; US Dept. of Health and Human Services. Public
Health CDC Service; 1985 p.42-3.
15. Allen B, Baker FJ. Mycobacteria: isolation, identification and
sensitivity testing. London: Butterworth, 1968.
16. Tuberculosis Research Centre. Chemotherapy of drug resistant
TB, The Tuberculosis Research Centre experience over 40
yrs. Indian J Tuberc 2000; 47 : 201-10.
17. Kivihya-Ndugga LEA, van Cleeff MRA, Githui WA, Nganga
LW, Kibuga DK, Odhiambo JA, et al. A comprehensive
Reprint requests: Dr Rajeswari Ramachandran, Deputy Director (Senior Grade), Tuberculosis Research Centre (ICMR)
Mayor V.R. Ramanathan Road, Chetput, Chennai 600031, India
email: rajerama@yahoo.com
comparison of Ziehl-Neelsen and fluorescence microscopy for
the diagnosis of tuberculosis in a resource-poor urban setting.
Int J Tuberc Lung Dis 2003; 7 : 1163–71.
18. Ulukanligil M, Aslan G, Tasci S. A comparative study on the
different staining methods and number of specimens for the
detection of Acid fast bacilli. Mem Inst Oswaldo Cruz. Rio de
Janeiro 2000; 95: 855-8.
19. Gaur SN, Dhingra VK, Rajpal S, Aggarwal JK, Meghna.
Tuberculosis in the elderly and their treatment outcome under
DOTS. Indian J Tuberc 2004; 51 : 83-7.
20. Arora VK. Singla N, Sarin R. Profile of geriatric patients under
DOTS in the Revised National Tuberculosis Control
Programme. Indian J Chest Dis Allied Sci 2003; 45 : 231-5.
21. Noeske J, Nguenko PN. Impact of resistance to anti-
tuberculosis drugs on treatment outcome using World Health
Organization standard regimens. Trans R Soc Trop Med Hyg
2002; 96 : 429-33.
458 INDIAN J MED RES, NOVEMBER 2007
